Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

Eligibility Criteria

• 1. Clinical diagnosis of dry AMD.
• 2. Ability to understand and give informed consent.
• 3. Adult male or female \>55 years of age.
• 4. Medically suitable to undergo vitrectomy and subretinal injection (\>60% on Karnofsky scale).
• 5. Postmenopausal if female (expected to be common for the age limitation), or the female partner of a male subject unable to father children.
• 6. If male, willing to use barrier and spermicidal contraception during the study.
• 1. Allergy or hypersensitivity to dilation drops or fluorescein.
• 2. Active major medical conditions limiting ability to participate in the study.
• 3. Active malignancy or treatment with chemotherapy.
• 4. Systemic immunosuppressant therapy within past six months.
• 5. History of toxoplasmosis, retinal histoplasmosis or tuberculosis.
• 6. Receipt of investigational product (IP) in a clinical trial within prior six months.
• 7. Any other medical condition, which, in the Investigator's judgment, will interfere with the subject's ability to comply with the protocol, compromises subject safety, or interferes with the interpretation of the study results.
• 8. Pregnant or nursing females.